



## Spyre Therapeutics to Participate in Upcoming November Investor Conferences

October 30, 2024

WALTHAM, Mass., Oct. 30, 2024 /[PRNewswire](#)/ -- Spyre Therapeutics, Inc. (NASDAQ: SYRE), a clinical-stage biotechnology company utilizing best-in-class antibody engineering, rational therapeutic combinations, and precision medicine approaches to target improved efficacy and convenience in the treatment of Inflammatory Bowel Disease ("IBD"), today announced that management will participate in the following upcoming investor conferences:

**Event: Guggenheim's Inaugural Healthcare Innovation Conference**

**Date:** Wednesday, November 13, 2024

**Time:** 2:30pm ET

**Event: Stifel 2024 Healthcare Conference**

**Date:** Monday, November 18, 2024

**Time:** 1:15 pm ET

**Event: Jefferies London Healthcare Conference**

**Date:** Wednesday, November 20, 2024

**Time:** 10:30 am GMT

Live audio webcasts and replays of these events will be available on the Spyre investor events website at <https://ir.spyre.com/events-and-presentations>.

### About Spyre Therapeutics

Spyre Therapeutics is a clinical-stage biotechnology company that aims to create next-generation inflammatory bowel disease (IBD) products by combining best-in-class antibody engineering, rational therapeutic combinations, and precision medicine approaches. Spyre's pipeline includes extended half-life antibodies targeting  $\alpha 4\beta 7$ , TL1A, and IL-23. For more information, visit Spyre's website at [www.spyre.com](http://www.spyre.com).

Follow Spyre Therapeutics on social media: @spyretx and LinkedIn

SOURCE Spyre Therapeutics, Inc.